Oct 1 (Reuters) – European Medicines Firm:
EMA’S HUMAN MEDICATIONS COMMITTEE (CHMP) HAS STARTED FIRST ‘ROLLING REVIEW’ OF A COVID-19 VACCINE
EMA SAYS START OF ROLLING REVIEW INDICATES THAT COMMITTEE HAS BEGAN ASSESSING FIRST BATCH OF DATA ON VACCINE, WHICH COME FROM LABORATORY RESEARCH STUDIES
EMA – EMA WILL FINISH ITS ASSESSMENT ACCORDING TO ITS USUAL STANDARDS FOR QUALITY, SECURITY AND EFFICIENCIES
EMA SAYS OVERALL REVIEW TIMELINE CAN NOT BE PROJECTION YET, PROCESS NEEDS TO BE SHORTER THAN A REGULAR EVALUATION DUE TO TIME GOT THROUGHOUT ROLLING REVIEW
EMA – ROLLING EVALUATION PROCESS HAS BEEN USED FORMERLY IN THE EVALUATION OF THE COVID-19 MEDICINE, VEKLURY
EMA-ROLLING REVIEW OF ASTRAZENECA-OXFORD COVID VACCINE TO CONTINUE UNTIL ENOUGH PROOF IS AVAILABLE TO ASSISTANCE FORMAL MARKETING AUTHORISATION APPLICATION Source text: ( bit.ly/ 3cLfm6B) Further business coverage:
for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up
https://covid19globalcases.com/brief-ema-starts-rolling-evaluation-of-astrazeneca-oxford-covid-19-vaccine/
Comments
Post a Comment